和元生物: 第三届董事会第二十二次会议决议公告

Group 1 - The company held its 22nd meeting of the third board of directors on June 10, 2025, with all seven directors present, complying with relevant laws and regulations [1][2] - The board approved the nomination of four candidates for the fourth board of non-independent directors, with a term of three years starting from the approval date by the shareholders' meeting [2][3] - The board also approved the nomination of four candidates for the fourth board of independent directors, with the same term conditions as the non-independent directors [2][3] Group 2 - The company decided to abolish the supervisory board and amend its articles of association to enhance corporate governance, with the supervisory board's powers being transferred to the audit committee of the board [3][4] - The board approved the formulation and revision of several internal governance systems to align with the latest amendments to the articles of association and relevant regulations [4] - A proposal was made to convene the second extraordinary general meeting of shareholders in 2025 on June 27, 2025, which was also approved by the board [4][5]